General Statement of Disclosure:

CONSULTING FEES/HONORARIA: BCRI(MODEST), Bayer Corporation(SIGNIFICANT), Janssen Pharmaceuticals, Inc(MODEST), Cardiovascular Research Foundation(MODEST), Johnson & Johnson Corp.(SIGNIFICANT), WebMD(MODEST), Gilead Sciences, Inc. (SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Novo Nordisk Inc.(MODEST), Boston Scientific(MODEST), CSL Behring (MODEST), Duke Clinical Research Institute(MODEST), Merck & Co., Inc.(MODEST), Somahlution(SIGNIFICANT), CSL Behring (SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), UpToDate in Cardiovascular Medicine (MODEST), Bioclinica(SIGNIFICANT), Daiichi Sankyo(MODEST), Daiichi Sankyo(MODEST), EXCITE International (NONE), Inari(SIGNIFICANT), MashUp MD(MODEST), MashUp MD(MODEST), MD Magazine(MODEST), MD Magazine(MODEST), MJHealth(MODEST), MjHealth(MODEST), Pfizer Inc(MODEST), PhaseBio(SIGNIFICANT), Revance therapeutics(SIGNIFICANT), Vectura(MODEST), Vectura(MODEST), Woman as one(MODEST), Women as One(MODEST), Angel Medical/Avertix Medical(SIGNIFICANT), Somahlution/Marizyme(SIGNIFICANT), Esperion(SIGNIFICANT), Adaptimmune(MODEST), Beren Therapeutics(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Samsung(SIGNIFICANT), SFJ(SIGNIFICANT), Amgen Inc.(MODEST), Anthos Therapeutics(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Cardenal Therapeutics(MODEST), Faraday(MODEST), HeartFlow(MODEST), Intellia Therapeutics (MODEST), Lexicon(MODEST), Lumanity(MODEST), Medscape(MODEST), Samsung(MODEST), SFJ(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Fortress Biotech(SIGNIFICANT), Fortress Biotech(SIGNIFICANT), Dyad Medical(MODEST), Lexaria(MODEST), Bridge Access Solutions(MODEST), Egnite(MODEST), Flow Therapy(MODEST), Generable(MODEST), HeartBeam(MODEST), Pramana(MODEST), Xevant(MODEST) OFFICER, DIRECTOR ETC: Baim Institute (SIGNIFICANT) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Tribe MD(MODEST) RESEARCH/RESEARCH GRANTS: Janssen Pharmaceuticals, Inc(SIGNIFICANT), Johnson & Johnson Corp.(SIGNIFICANT), CSL Behring(SIGNIFICANT), Bristol-Myers Squibb Company (NONE), SCAD Alliance(NONE) OTHER FINANCIAL BENEFIT: nference (MODEST)

View Full Disclosure